NCT02086903 is a Phase 3 clinical trial of Ticagrelor 90 mg in Pharmacodynamics, sponsored by Dong-A University.

Who is sponsoring NCT02086903?

NCT02086903 is sponsored by Dong-A University.

What drugs are being tested in NCT02086903?

Interventions in NCT02086903: Ticagrelor 90 mg, Clopidogrel 600 mg.

What condition does NCT02086903 study?

NCT02086903 studies Pharmacodynamics.

Is NCT02086903 still recruiting?

NCT02086903 is currently completed. Last updated 28 January 2020.

Last reviewed 2020-01-28 · How we verify

NCT02086903

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacodynamic Effect of Loading And Maintenance Doses Of Clopidogrel Versus Half Doses of Ticagrelor In Healthy Subjects

Completed Phase 3 Last updated 28 January 2020

What this trial tests

Phase 3 trial testing Ticagrelor 90 mg in Pharmacodynamics in 12 participants. Completed in 1 May 2014.

Timeline

1 February 2014

Primary endpoint
1 April 2014

1 May 2014

Quick facts

Lead sponsor	Dong-A University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	health services research
Enrollment	12
Start date	1 February 2014
Primary completion	1 April 2014
Estimated completion	1 May 2014
Sites	1 location across South Korea

Drugs / interventions tested

Ticagrelor 90 mg — full drug profile →
Clopidogrel 600 mg — full drug profile →

Conditions studied

Pharmacodynamics — all drugs for Pharmacodynamics →

Sponsor

Dong-A University

Who can join

Adults 19 to 59, male only, with Pharmacodynamics. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Platelet reactivity
Time frame: up to 122 hours
Platelet reactivity will be measured using multiple platelet function tests, including, light transmission aggregometry (LTA), multiple electrode platelet aggregometry (MEA, Dynabyte Medical, Munich, Germany), VerifyNow (Accumetrics, San Diego, CA, USA), Total thrombus-formation analysis system (T-TAS®, Fujimori Kogyo, Japan). The platelet reactivity will be measured at 0.5, 2, 6, 24,26,120,122 ho

Sponsor's own description

To evaluate the pharmacodynamics of a lower Ticagrelor dose in healthy Korean volunteers compared with standard Clopidogrel agent.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ticagrelor 90 mg

Trials testing the same drug.

NCT06691191 — Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors · Phase 4 · recruiting
NCT05183178 — Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome · Phase 4 · unknown
NCT03620760 — Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation · Phase 4 · unknown
NCT03614832 — Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD · Phase 4 · unknown
NCT03251859 — Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study · Phase 3 · completed

Other recruiting trials for Pharmacodynamics

Currently open trials in the same condition.

NCT06469450 — KF2023#1-Trial: Influence of Statin Intake on Cellular Readouts · Phase 1 · recruiting

Other Dong-A University trials

Trials by the same sponsor.

NCT04755387 — Ticagrelor De-escalation Strategy in AMI Patients · Phase 4 · recruiting
NCT05225077 — Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients · Phase 4 · unknown
NCT05210595 — Optimal Dosage of Ticagrelor in Korean Patients With AMI · Phase 4 · unknown
NCT04174456 — Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy · NA · unknown
NCT03570671 — Noninvasive Cardiac Imaging in Vasospastic Angina Korean Registry (NAVIGATOR) · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02086903 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dong-A University
Last refreshed: 28 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02086903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing